Mentari Therapeutics to Present at Upcoming Investor Conferences
Mentari Therapeutics (Nasdaq: MTRI) announced that management will participate in three investor conferences in November, beginning November 9.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mentari Therapeutics (Nasdaq: MTRI) announced that management will participate in three investor conferences in November, beginning November 9.
The schedule includes Guggenheim on November 9 at 4:00 p.m. ET, Stifel on November 12 at 10:00 a.m. ET, and Jefferies in London on November 17 at 11:00 a.m. GMT. Live webcasts and archived recordings will be available on Mentari’s website for 90 days following each conference.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mentari Therapeutics, Inc. (Nasdaq: MTRI), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced that members of management will participate in the following upcoming investor conferences in November:
Guggenheim 3rd Annual Healthcare Innovation Conference
- Date: Monday, November 9
- Time: 4:00 p.m. ET
Stifel 2026 Healthcare Conference
- Date: Thursday, November 12
- Time: 10:00 a.m. ET
2026 Jefferies Global Healthcare Conference in London
- Date: Tuesday, November 17
- Time: 11:00 a.m. GMT
Live webcasts of these events, as well as archived recordings, will be available on Mentari’s website for 90 days following each conference.
About Mentari Therapeutics
Mentari Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for the prevention of migraine, a condition affecting more than 1 billion people globally. Mentari's lead programs are MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-PACAP and anti-CGRP bispecific antibody with the potential to deliver greater efficacy for people with incomplete response to existing therapies. Mentari is advancing a robust portfolio of potentially best-in-class therapies that target validated pathways in migraine biology. The company’s programs were discovered by Paragon. Mentari Therapeutics is based in Waltham, MA. For more information, visit mentaritx.com. Follow us on LinkedIn.
Investor Contact:
investors@mentaritx.com
Media Contact:
media@mentaritx.com
